Loading…
Rocket Pharmaceuticals, Inc. is projected to decline to $2.89 by 2027, a -3% move from its current price of $2.99. RCKT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.89 | $2.99 | $3.09 | -0.04% |
| May 30 | $2.85 | $2.99 | $3.13 | -0.07% |
| May 31 | $2.82 | $2.99 | $3.16 | -0.11% |
| Jun 1 | $2.79 | $2.99 | $3.19 | -0.15% |
| Jun 2 | $2.77 | $2.98 | $3.21 | -0.18% |
| Jun 3 | $2.75 | $2.98 | $3.24 | -0.22% |
| Jun 4 | $2.73 | $2.98 | $3.26 | -0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.73 | $2.98 | $3.26 | -0.25% |
| Week 2 | $2.63 | $2.97 | $3.37 | -0.51% |
| Week 3 | $2.55 | $2.97 | $3.45 | -0.76% |
| Week 4 | $2.48 | $2.96 | $3.53 | -1.01% |
| Week 5 | $2.43 | $2.95 | $3.59 | -1.26% |
| Week 6 | $2.38 | $2.94 | $3.65 | -1.52% |
| Week 7 | $2.33 | $2.94 | $3.70 | -1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rocket Pharmaceuticals, Inc. is a healthcare company that operates as a late-stage biotechnology business focused on developing, manufacturing, and selling genetic therapies for rare and devastating diseases in the United States.
The company pursues in vivo adeno-associated viral (AAV) programs, including Danon disease (RP-A501) in Phase 2 and Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601) in Phase 1, along with BAG3 Dilated Cardiomyopathy (BAG3-DCM) in preclinical stage. It also develops ex vivo lentiviral (LV) programs for Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102), and Pyruvate Kinase Deficiency (RP-L301).
Rocket maintains license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas; Centro de Investigacion Biomedica En Red de Enfermedades Raras; Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. The company was founded in 1999 and is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals, Inc. (RCKT) is a healthcare company with a current price of $2.96 and a market capitalization of $323.21M. It is ranked 3450 in its market cohort.
The near-term outlook shows a relatively flat path through 2026, with 2026 values of min $2.92, avg $2.96, max $3.68 and an ROI of 0, indicating neutral momentum.
From 2030 onward, the forecast turns bullish, with the 2030 average price at $3.91 and a max of $6.03, delivering a 32.1 ROI. The risk/reward profile remains skewed to upside through 2050, which carries an average near $11.18 and a max of $22.88 with a 277.8 ROI.
Overall, the forecast implies potential upside over the long horizon, but readers should treat these as estimates rather than guarantees and consider the inherent uncertainty in biotech equities.
A major floor 23.6% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.3% away) — a key level to hold.
The nearest ceiling, 30.8% above — a clean break opens room to run.
A major ceiling 77.3% above — clearing it would confirm fresh momentum.
Key RCKT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCKT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.01 | Sell | $3.02 | Sell |
| MA 10 | $3.13 | Sell | $3.13 | Sell |
| MA 20 | $3.37 | Sell | $3.30 | Sell |
| MA 50 | $3.66 | Sell | $3.56 | Sell |
| MA 100 | $3.79 | Sell | $3.68 | Sell |
| MA 200 | $3.57 | Sell | $4.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 35.67 | Neutral |
| Stoch RSI (14) | 32.38 | Neutral |
| CCI (20) | -94.29 | Neutral |
| Williams %R (14) | -90.67 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -17.63 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 9.33 | Buy |
| TRIX (15) | -0.65 | Sell |
| Awesome (5,34) | -0.49 | Sell |
| Ultimate (7,14,28) | 28.64 | Buy |
| Momentum (10) | -0.65 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 2.96 | Buy |
| ADX (14) | 20.82 | Sell |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is Neutral overall. The RSI (14) sits at 30, with the 50-day simple moving average at $3.73 and the 200-day simple moving average at $3.57. Immediate support is listed at $2.92 and resistance at $3.91.
The thirty-day range spans from $2.35 to $3.73, signaling a compressed near-term trading band. Implied volatility runs high at 70%, underscoring notable near-term risk and potential for outsized moves on news or data releases.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.92 | $2.99 | $3.72 | 0% | Neutral | |
| $2.24 | $2.89 | $3.97 | -3% | Neutral | |
| $2.27 | $3.02 | $4.32 | +1% | Neutral | |
| $2.49 | $3.40 | $5.04 | +14% | Neutral | |
| $2.88 | $4.04 | $6.15 | +35% | Bullish | |
| $2.93 | $4.21 | $6.57 | +41% | Bullish | |
| $3.11 | $4.57 | $7.29 | +53% | Bullish | |
| $3.07 | $4.60 | $7.47 | +54% | Bullish | |
| $2.77 | $4.24 | $7.01 | +42% | Bullish | |
| $3.00 | $4.67 | $7.86 | +56% | Bullish | |
| $3.96 | $6.73 | $12.13 | +125% | Bullish | |
| $5.97 | $11.85 | $23.65 | +296% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.92 | $2.99 | $3.51 | +0.00% |
| June 2026 | $2.46 | $2.90 | $3.51 | -3.01% |
| July 2026 | $2.43 | $2.89 | $3.56 | -0.26% |
| August 2026 | $2.49 | $2.99 | $3.73 | +3.51% |
| September 2026 | $2.45 | $2.96 | $3.73 | -1.09% |
| October 2026 | $2.33 | $2.84 | $3.61 | -4.14% |
| November 2026 | $2.33 | $2.85 | $3.65 | +0.44% |
| December 2026 | $2.35 | $2.89 | $3.72 | +1.26% |
Click any year to see its month-by-month RCKT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, RCKT is projected to trade between $2.92 and $3.72, averaging $2.99 — a potential gain of 0% from today's $2.99. A consolidation phase looks the most probable path here.
Rocket Pharmaceuticals, Inc.'s 2027 outlook centres on $2.89, within a $2.24 to $3.97 range. That is -3% versus the projected 2026 average. That marks a -3% change versus current levels. Price action looks broadly range-bound.
By 2028, RCKT could reach as high as $4.32, with a base case around $3.02 and support toward $2.27 — roughly +1% from $2.99. A consolidation phase looks the most probable path here.
Expect RCKT to range from $2.49 to $5.04 through 2029. The $3.40 average target implies a +14% move from current prices. That is up +13% on the projected 2028 average. Price action looks broadly range-bound.
The RCKT price prediction for 2030 points to an average of $4.04 (low $2.88, high $6.15) — a potential gain of +35% on today's $2.99. Buyers look set to stay in control over this stretch.
In 2031, RCKT is projected to trade between $2.93 and $6.57, averaging $4.21 — a potential gain of +41% from today's $2.99. That is up +4% on the projected 2030 average. Momentum favours further upside here.
Rocket Pharmaceuticals, Inc.'s 2032 outlook centres on $4.57, within a $3.11 to $7.29 range. That is up +9% on the projected 2031 average. That marks a +53% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, RCKT could reach as high as $7.47, with a base case around $4.60 and support toward $3.07 — roughly +54% from $2.99. Momentum favours further upside here.
Expect RCKT to range from $2.77 to $7.01 through 2034. The $4.24 average target implies a +42% move from current prices. That is -8% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The RCKT price prediction for 2035 points to an average of $4.67 (low $3.00, high $7.86) — a potential gain of +56% on today's $2.99. Momentum favours further upside here.
In 2040, RCKT is projected to trade between $3.96 and $12.13, averaging $6.73 — a potential gain of +125% from today's $2.99. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Rocket Pharmaceuticals, Inc.'s 2050 outlook centres on $11.85, within a $5.97 to $23.65 range. That is up +76% on the projected 2040 average. That marks a +296% change versus current levels. Momentum favours further upside here.
Investing $1,000 in RCKT today (≈ 334.448161 RCKT) could be worth
$3,962.06
+$2,962.06 (+296%) by 2050 · US Dollar
Based on the average projected RCKT price of $11.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCKTwould be worth at today's price.
$1,000 invested in RCKT on May 27, 2025 (≈ 429.184563 RCKT) would be worth
$1,283.26
+$283.26 (+28.3%) today · 1.28× · US Dollar
Based on a RCKT entry price of $2.33 vs. today's $2.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.97 | $1,006.73 | +0.7% |
| 1 month ago | $3.49 | $856.73 | -14.3% |
| 3 months ago | $4.53 | $660.04 | -34.0% |
| 6 months ago | $3.42 | $874.27 | -12.6% |
| 1 year ago | $2.33 | $1,283.26 | +28.3% |
| All time (5.0y) ago | $41.73 | $71.65 | -92.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCKT forecast.
Our base-case forecast reaches $6.00 around 2040.
Implied market cap at $6.00: $655.16M
The multi-year forecast shows a gradual lifting of price expectations into the 2030s and beyond. In 2030, the average price is projected at $3.91 with a 32.1 ROI, followed by continued expansion through 2031 (avg $4.14; ROI 39.7) and 2032 (avg $4.44; ROI 50.1).
The uptrend continues through 2033 (avg $4.43; ROI 49.8) and 2034 (avg $4.09; ROI 38), with 2035 (avg $4.46; ROI 50.8) signaling sustained bullish sentiment. By 2040, the average is forecast at $6.49 with a 119.3 ROI, and by 2050 the average is $11.18 with a 277.8 ROI, while the max prices rise to $11.96 in 2040 and $22.88 in 2050.
These are projections, not guarantees, and carry the usual biotech risk. The path depicts meaningful upside in the long run but also the potential for volatility and drawdowns in the near term given the sector and program-stage dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $3.91 with a 32.1 ROI.
Forecasts indicate a bullish trajectory beginning in 2030 with rising averages through 2050 (e.g., avg $3.91 in 2030 and avg $11.18 in 2050, with max as high as $22.88). However, these are estimates and subject to risk; no guarantees are implied.
Yes. The 2030 forecast lists a max of $6.03, and the 2040 max is $11.96, with the 2050 max at $22.88.
Current price is $2.96 and market capitalization is $323.21M.
Near-term sentiment is NEUTRAL. RSI(14) is 30, with SMA50 at $3.73 and SMA200 at $3.57. Support is $2.92 and resistance is $3.91; the 30-day range is $2.35-$3.73.
Rocket Pharmaceuticals, Inc. Community Discussion
0Share your Rocket Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.